drugset / Trial / NCT06479863
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
Timeline
- Start
- 2024-08-08
- Primary completion
- 2027-05-30
- Completion
- 2027-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemdisiran | Small interfering RNA (siRNA) | 200 mg | Subcutaneous |
| Subject | Pozelimab | Monoclonal antibody | 200 mg | Subcutaneous |